Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Dithranol in lassar's paste		Unlicensed specials available in varying strengths
Dithranol pomade 0.4% w/w		Unlicensed special
Dobutamine injection		Hospital use only
Docetaxel injection	TA214 - Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer TA109 - Docetaxel for the adjuvant treatment of early node-positive breast cancer TA101 - Docetaxel for the treatment of hormone-refractory metastatic prostate cancer	Negative TA
Domperidone tablets		For short term use only
Dopamine injection		Hospital use only
Dornase alpha nebuliser solution (Pulmozyme)
Doxapram
Doxapram injection		Hospital only
Doxorubicin injection	TA91 - Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.